Phase 3 trial in 2354 patients with higher-risk early breast cancer after lumpectomy (2255 analysed): concurrent boost during whole-breast irradiation was non-inferior to sequential boost for in-breast recurrence (5-year 1.9% vs 2.1%), with no worse toxicity.
RCTn = 2,354
Vicini et al. Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial